WO2008082673A3 - Companion diagnostic assays for cancer therapy - Google Patents

Companion diagnostic assays for cancer therapy Download PDF

Info

Publication number
WO2008082673A3
WO2008082673A3 PCT/US2007/026526 US2007026526W WO2008082673A3 WO 2008082673 A3 WO2008082673 A3 WO 2008082673A3 US 2007026526 W US2007026526 W US 2007026526W WO 2008082673 A3 WO2008082673 A3 WO 2008082673A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
cancer therapy
diagnostic assays
companion diagnostic
absence
Prior art date
Application number
PCT/US2007/026526
Other languages
French (fr)
Other versions
WO2008082673A2 (en
WO2008082673A8 (en
Inventor
Dimitri Semizarov
Evelyn M Mckeegan
Rick R Lesniewski
Christin Tse
Gang Wang
Original Assignee
Abbott Lab
Dimitri Semizarov
Evelyn M Mckeegan
Rick R Lesniewski
Christin Tse
Gang Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/646,910 external-priority patent/US20080233567A1/en
Application filed by Abbott Lab, Dimitri Semizarov, Evelyn M Mckeegan, Rick R Lesniewski, Christin Tse, Gang Wang filed Critical Abbott Lab
Publication of WO2008082673A2 publication Critical patent/WO2008082673A2/en
Publication of WO2008082673A3 publication Critical patent/WO2008082673A3/en
Publication of WO2008082673A8 publication Critical patent/WO2008082673A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for classifying cancer patients as eligible to receive cancer therapy comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy, such as therapy with a Bcl-2 family inhibitor, and for monitoring patient response to therapy.
PCT/US2007/026526 2006-12-28 2007-12-28 Companion diagnostic assays for cancer therapy WO2008082673A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/646,910 US20080233567A1 (en) 2006-09-05 2006-12-28 Companion diagnostic assays for cancer therapy
US11/646,910 2006-12-28

Publications (3)

Publication Number Publication Date
WO2008082673A2 WO2008082673A2 (en) 2008-07-10
WO2008082673A3 true WO2008082673A3 (en) 2009-01-22
WO2008082673A8 WO2008082673A8 (en) 2009-07-09

Family

ID=39589134

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/026526 WO2008082673A2 (en) 2006-12-28 2007-12-28 Companion diagnostic assays for cancer therapy
PCT/US2007/026471 WO2008082643A2 (en) 2006-12-28 2007-12-28 Companion diagnostic assays for cancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026471 WO2008082643A2 (en) 2006-12-28 2007-12-28 Companion diagnostic assays for cancer therapy

Country Status (1)

Country Link
WO (2) WO2008082673A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
JP2012517241A (en) * 2009-02-11 2012-08-02 アボット・ラボラトリーズ Methods and compositions for identifying, classifying and monitoring subjects with Bcl-2 family inhibitor resistant tumors and cancers
EP2491140A1 (en) * 2009-10-19 2012-08-29 Stichting Het Nederlands Kanker Instituut Predicting response to anti-cancer therapy via array comparative genomic hybridization
EP2491141A2 (en) * 2009-10-19 2012-08-29 Stichting Het Nederlands Kanker Instituut Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization
EP2491139A1 (en) * 2009-10-19 2012-08-29 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
WO2012038837A2 (en) * 2010-09-20 2012-03-29 Stichting Het Nederlands Kanker Instituut Methods for predicting response to anti-cancer therapy in cancer patients
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715041A1 (en) * 2004-02-13 2006-10-25 BML, Inc. Method of detecting cancer cell acquiring drug-resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192937B2 (en) * 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715041A1 (en) * 2004-02-13 2006-10-25 BML, Inc. Method of detecting cancer cell acquiring drug-resistance

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GALTELAND E. ET AL.,: "translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-Cell non-hodgkin's lymphomas", LEUKEMIA, vol. 19, 2005, pages 2313 - 2323, XP002491256 *
GIRARD L ET AL: "Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4894 - 4906, XP003015739 *
HOSOE S. ET AL.,: "a frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of lung", CANCER RESEARCH, vol. 54, 1 April 1994 (1994-04-01), pages 1787 - 1790, XP002503412 *
LEVIN N A ET AL: "IDENTIFICATION OF NOVEL REGIONS OF ALTERED DNA COPY NUMBER IN SMALL CELL LUNG TUMORS", GENES, CHROMOSOMES & CANCER, XX, XX, vol. 13, no. 3, 1 January 1995 (1995-01-01), pages 175 - 185, XP008038794 *
MONNI O. ET AL.,: "BCL2 overexpression associated with chromosomal amplification in diffuse large b-cell lymphoma", BLOOD, vol. 90, no. 3, 1 August 1997 (1997-08-01), pages 1168 - 1174, XP002491254 *
OLTERSDORF T. ET AL.,: "an inhibitor of BCL-2 family proteins induces regression of solid tumours", NATURE, vol. 435, 2 June 2005 (2005-06-02), pages 677 - 681, XP002491257 *
WALCH A.K. ET AL.,: "typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparitive genomic hybridization", AM. J. PATHOLOGY, vol. 153, no. 4, October 1998 (1998-10-01), pages 1089 - 1098, XP002503413 *
WERNER C.A. ET AL.,: "high-level dna amplifications are common genetic aberrations in b-cell neoplasms", AM. J. PATHOLOGY, vol. 151, no. 2, August 1997 (1997-08-01), pages 335 - 342, XP002491255 *
YASUI K ET AL: "Alteration in copy numbers of genes as a mechanism for acquired drug resistance", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 64, 15 February 2004 (2004-02-15), pages 1403 - 1410, XP002980904, ISSN: 0008-5472 *
ZHAO XIAOJUN ET AL: "Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, USA, DE, vol. 65, no. 13, 1 July 2005 (2005-07-01), pages 5561 - 5570, XP002411064 *

Also Published As

Publication number Publication date
WO2008082673A2 (en) 2008-07-10
WO2008082673A8 (en) 2009-07-09
WO2008082643A3 (en) 2008-11-06
WO2008082643A2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2008082673A8 (en) Companion diagnostic assays for cancer therapy
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2006041959A8 (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
WO2007137187A3 (en) System and method for determining individualized medical intervention for a disease state
WO2007079284A3 (en) Lung cancer diagnostic assay
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2007098444A3 (en) Methods for analysis of extracellular rna species
WO2011015602A3 (en) Lung cancer biomarkers
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2008021290A3 (en) Organ-specific proteins and methods of their use
WO2007022511A3 (en) Listeria-induced immunorecruitment and activation, and methods of use thereof
WO2006108087A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2006047536A3 (en) Methods and kits for detecting mutations
EP1724586A3 (en) Annexin for cancer risk assessment
WO2007079250A3 (en) Devices and methods for enrichment and alteration of circulating tumor cells and other particles
WO2009019368A3 (en) Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2005095651A3 (en) Molecular markers of cisplatin resistance in cancer and uses thereof
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2008054764A3 (en) Biomarkers for colorectal cancer
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870929

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07870929

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)